Browse Studies — Arctuva

Phase 1

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come b…

Colorectal CarcinomaEndometrial CarcinomaMelanoma+19 more

Estimated

~$10 – $7,500

Children's Oncology GroupNCT04851119

Phase 1

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back…

Recurrent Solid TumorRecurrent Ewing SarcomaRecurrent Hepatoblastoma+19 more

Estimated

~$10 – $6,250

Phase 1

A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma.

This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP…

Refractory Ewing SarcomaRelapsed Ewing SarcomaEwing Sarcoma

Estimated

~$10 – $8,750

Jazz PharmaceuticalsNCT05734066